NASDAQ · Biotechnology · USD
Indaptus Therapeutics, Inc. (INDP) Stock Analysis
Indaptus Therapeutics, Inc. (INDP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
INDP Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.93
- Previous Close
- $2.96
- Day's Range
- 2.85–3.28
- 52-Week Range
- 0.92–5.96
- Volume
- 527.54K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.97
Valuation
- Market Cap
- $421.05M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −6.15
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$20.85M
- Shares Outstanding
- 133.24M
- 1-Year Return
- −11.98%
Dividend and dates
- Avg Volume
- 887.96K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, INDP closed at $3.16, −11.98% over 1 year.
Indaptus Therapeutics, Inc. (INDP) has a market capitalization of $421.05M.
In fiscal 2025, INDP reported revenue of $0.00.
INDP Stock Return by Calendar Year
Indaptus Therapeutics, Inc. (INDP) 10-year return: what $10,000 became
- 1 year
- $10,000 $8,802
- −11.98%
- 5 years
- $10,000 $146
- −98.54%
- 10 years
- $10,000 $3
- −99.97%
If you had invested $10,000 in Indaptus Therapeutics, Inc. (INDP) 10 years ago, at the close on October 21, 2016, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −56.05% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +8.59% |
| 2025 | −87.66% |
| 2024 | −52.16% |
| 2023 | +21.38% |
| 2022 | −74.56% |
| 2021 | −58.70% |
| 2020 | −65.50% |
| 2019 | −93.37% |
| 2018 | +46.41% |
| 2017 | −9.65% |
| 2016 (partial year) | −1.89% |
As of October 21, 2026.
INDP Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$20.85M | — |
| 2024 | $0.00 | −$15.02M | — |
| 2023 | $0.00 | −$15.42M | — |
| 2022 | $0.00 | −$14.32M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$19.83M | −$20.85M | — |
| 2024 | $0.00 | — | −$15.37M | −$15.02M | — |
| 2023 | $0.00 | — | −$16.38M | −$15.42M | — |
| 2022 | $0.00 | — | −$14.91M | −$14.32M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Indaptus Therapeutics Announces Private Placement Of 20,338,974 Shares For Gross Proceeds Of ~$24M
BenzingaIndaptus Therapeutics Files Prospectus Related To The Proposed Resale Of Up To 58,895,000 Shares Of Common Stock By Selling Stockholders
BenzingaIndaptus Therapeutics Q2 EPS $(0.02) Beats $(1.57) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B